BioMed Central | Articles which cite: In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

printer friendly

to [Help]

PubMed Central articles that cite the above article:

1.	Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M J Virol 2008 Jan, 82:764-74 [PubMed Central] [PubMed] [Related articles]
2.	Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. Myers RE, Pillay D J Virol 2008 Sep, 82:9228-35 [PubMed Central] [PubMed] [Related articles]
3.	HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. Shafer RW, Schapiro JM AIDS Rev 2008 Apr-Jun, 10:67-84 [PubMed Central] [PubMed] [Related articles]
4.	Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K J Virol 2008 Nov, 82:10366-74 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 4 articles in BioMed Central

You can also check ISI Web of Science for additional citations (subscription required)

printer friendly

to [Help]